Vaccines against HPV (human papillomavirus) protect against the most common HP viruses that can cause cervical cancer and tumors in the mouth, throat, genital and anus area.
| Name | Description | Marketing Authorisation Holder | Kind of Vaccine | License Number | License Date | Further Information |
|---|---|---|---|---|---|---|
|
Cervarix |
Humaner Papillomvirusimpfstoff (Typen 16, 18) Verwendung ab einem Lebensalter von 9 Jahren / Use from 9 years of age onwards |
GlaxoSmithKline Biologicals S.A. |
Mono | EU/1/07/419/001-012 | 20.09.2007 | |
|
Gardasil |
Humaner Papillomvirusimpfstoff (Typen 6, 11, 16, 18) Verwendung ab einem Lebensalter von 9 Jahren / Use from 9 years of age onwards |
Merck Sharp & Dohme B.V. |
Mono | EU/1/06/357/001-021 | 20.09.2006 | |
|
Gardasil 9 |
9-valenter Humaner Papillomvirusimpfstoff (Typen 6, 11, 16, 18, 31, 33, 45, 52, 58) Verwendung ab einem Lebensalter von 9 Jahren / Use from 9 years of age onwards |
Merck Sharp & Dohme B.V. |
Mono | EU/1/15/1007 | 10.06.2015 |
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 528 in BAnz AT 25.04.2025 B4.
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.
Updated: 25.04.2025
